Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 25, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The primary material change disclosed is a reduction in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Previous Holding: 18,371,975 ADRs
- New Holding: 18,336,331 ADRs
- Change: Decrease of 35,644 ADRs
- Transaction Date: July 21, 2005
- Average Price: $47.99
This change resulted from a movement in the fund. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the fund movement on the total share count held by the US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.
- Note that this filing does not contain financial performance data for the period.